Enzon Pharmaceuticals, Inc. is a biotechnology company. It discovers, develops, and commercializes therapeutics to treat life-threatening diseases. The Company's marketed drug products include PegIntron (R) for chronic hepatitis C; Sylatron (R) for Melanoma; Macugen (R) for neovascular age-related macular degeneration; CIMZIA (R) for Crohn's disease; Oncaspar for acute lymphoblastic leukemia; and Adagen for severe combined immunedeficiency. Enzon Pharmaceuticals, Inc. is headquartered in Piscataway, New Jersey.
| Revenue (Most Recent Fiscal Year) | $0.03M |
| Net Income (Most Recent Fiscal Year) | $0.78M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 3.43 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 8.60 |
| Pre-Tax Margin (Trailing 12 Months) | 1150.00% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -22.19% |
| Return on Assets (Trailing 12 Months) | -1.28% |
| Current Ratio (Most Recent Fiscal Quarter) | 82.17 |
| Quick Ratio (Most Recent Fiscal Quarter) | 82.17 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $0.03 |
| Earnings per Share (Most Recent Fiscal Quarter) | -- |
| Earnings per Share (Most Recent Fiscal Year) | -- |
| Diluted Earnings per Share (Trailing 12 Months) | $-0.01 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 74.21M |
| Free Float | 73.92M |
| Market Capitalization | $6.69M |
| Average Volume (Last 20 Days) | 0.01M |
| Beta (Past 60 Months) | 0.25 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 0.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 0.00% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |